Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
-
23/04/2025, 12:34
-
ansa.it
0
Scopri altro
- oggi, 12:12
-
repubblica.it
-
0
- 23/06/2025, 12:34
-
ansa.it
-
0
- 23/06/2025, 12:22
-
ansa.it
-
0
- 23/06/2025, 12:22
-
ansa.it
-
0
- 23/06/2025, 12:15
-
ansa.it
-
0
- 23/06/2025, 12:09
-
ansa.it
-
0
- 23/06/2025, 12:09
-
ansa.it
-
0
- 23/06/2025, 12:01
-
ansa.it
-
0
Nessun commento